We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Final Guidance on Submitting ANDAs, Highlighting Recurring Deficiencies
FDA Issues Final Guidance on Submitting ANDAs, Highlighting Recurring Deficiencies
The FDA, as part of its Drug Competition Action Plan, has released final guidance for companies preparing to submit abbreviated new drug applications (ANDAs) to the agency for generic products.